Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
22.92 USD | -4.02% | +1.49% | -25.11% |
04-15 | Intellia Therapeutics, Inc. Appoints Michael P. Dube as Principal Accounting Officer | CI |
03-25 | Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-25.11% | 2.3B | |
+22.56% | 46.4B | |
-1.83% | 41.75B | |
+48.83% | 41.37B | |
-3.42% | 29.71B | |
+10.35% | 26.01B | |
-19.24% | 19.52B | |
+27.73% | 12.43B | |
0.00% | 12.18B | |
-0.80% | 12.13B |
- Stock Market
- Equities
- NTLA Stock
- News Intellia Therapeutics, Inc.
- Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals